Breast cancer after ovarian cancer in BRCA1 and BRCA2 pathogenic variant heterozygotes: Lower rates for 5 years post chemotherapy.
D Gareth EvansRobert D MorganEmma J CrosbieSacha J HowellClaire FordeAnthony HowellFiona LallooEmma R WoodwardPublished in: Genetics in medicine : official journal of the American College of Medical Genetics (2024)
Women can be reassured that incidence of breast cancer after ovarian cancer diagnosis is relatively low. It appears likely that this effect is due to platinum-based chemotherapy. Nonetheless women need to be aware that incidence increases thereafter, especially after 10 years.